Shots:

• The EC has approved Altuvoct to treat & prevent bleeds and perioperative prophylaxis in haemophilia A and granted ODD, providing it 10yrs. of market exclusivity
• The authorization was supported by two P-III studies, XTEND-1 (n=159; ≥12yrs.) assessing Altuvoct across the prophylaxis arm (52wks.) & on-demand arm (26wks. followed by switching to weekly prophylaxis 26wks. more) & XTEND-Kids (n=74; <12yrs.) assessing prophylactic Altuvoct in previously treated severe haemophilia A patients
• Studies showed that Altuvoct prophylaxis (50 IU/kg, QW) reduced bleeding regardless of age (mean ABR<1, 80-88% bleed-free) as well as improved joint health, physical health, pain & quality of life at 52wks. without factor VIII inhibitors

Ref: Sobi | Image: Sobi

Related News:- Sanofi and Sobi Present P-III Study (XTEND-Kids) Results of Altuviiio for Severe Hemophilia A at ISTH 2023

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com